Vandraas K, Naume B, Sætersdal A, Blix E(2026) HER2-positiv brystkreft Tidsskr Nor Laegeforen, 146(10) DOI 10.4045/tidsskr.26.0199, PubMed 42708992
Vandraas KF, Hjorth S, Trewin-Nybråten CB, Andreassen BK, Blix ES, Naume B, Botteri E, Ursin G, Støer NC(2026) Translating CLEOPATRA into routine practice: National treatment patterns and survival for patients with HER2-positive metastatic breast cancer Breast, 89, 104852 DOI 10.1016/j.breast.2026.104852, PubMed 42385477
Pagani O, Niman SM, Ruggeri M, Peccatori FA, Azim HA, Colleoni M, Saura C, Shimizu C, Sætersdal AB, Kroep JR, Warner E, Amant F, Mailliez A, Moore HCF, Ruiz-Borrego M, Walshe JM, Borges VF, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Lee JE, Saunders C, Bjelic-Radisic V, Susnjar S, Cardoso F, Klar NJ, Ferreiro T, Ribi Ket al.(2026) Updated results of the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) trial Ann Oncol, 37(9), 1230-1241 DOI 10.1016/j.annonc.2026.05.699, PubMed 42214557
